Hiren Mehta
Pulmonary Disease · Raleigh, NCNPI 1235339599
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,096 of the $75,942 with a category attached, or 63.3%. 26 manufacturers reported payments, led by Medtronic at 46.0% of the total. 2025 is the largest year on record at $26,554, more than ten times the $2,243 reported in 2019. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $387.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$35K
- Intuitive Surgical$35K
- Covidien LP$4K
- Noah Medical Corporation$724
- GSK$295
- Galvanize Therapeutics, Inc$275
- plus $855 from 20 others
What the payments were for
- Speaking & faculty fees$48,09663%
- Travel & lodging$8,12411%
- Food & beverage$3,6155%
- Education$16,10821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 46 | $34,902 |
| Intuitive Surgical | 63 | $34,838 |
| Covidien LP | 7 | $4,051 |
| Noah Medical Corporation | 2 | $724 |
| GSK | 19 | $295 |
| Galvanize Therapeutics, Inc | 4 | $275 |
| Boehringer Ingelheim | 10 | $224 |
| AstraZeneca | 7 | $104 |
| United Therapeutics Corporation | 14 | $91 |
| Philips North America LLC | 5 | $90 |
| Inogen, Inc. | 3 | $44 |
| Grifols USA, LLC | 1 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Sanofi | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| CSL Behring | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Electromed, Inc. | 1 | $13 |
| Breathe Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$34,076
- ILLUMISITE$29,507
- superDimension$7,594
- ALIYA SYSTEM$242
- GALAXY$168
How this compares
$75,942 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 418 | $328,147 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 261 | $143,524 |
| Breo ElliptaFluticasone/Vilanterol | 246 | $130,459 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 149 | $87,942 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $86,299 |
| Spiriva RespimatTiotropium Bromide | 136 | $83,969 |
| Fasenra PenBenralizumab | 12 | $66,236 |
| Arnuity ElliptaFluticasone Furoate | 87 | $24,309 |
| Advair HfaFluticasone Propion/Salmeterol | 73 | $23,785 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $22,259 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 101 | $16,475 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $15,369 |
| Varenicline Tartrate | 60 | $12,775 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 28 | $11,013 |
| Wixela InhubFluticasone Propion/Salmeterol | 86 | $9,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $295 | $648,6991,053 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $224 | $171,911285 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $104 | $112,681189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Raleigh
- Vikas PathakRaleigh$32K
- William HallRaleigh$21K
- Navreet SindhwaniRaleigh$15K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.